Linked Life Data

15900595

Source:http://linkedlifedata.com/resource/pubmed/id/15900595

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-9-21
pubmed:abstractText
Cisplatin-based (CDDP-based) adjuvant chemotherapy of non-small cell lung cancer (NSCLC) was reported to yield 5-15% improvement in 5-year survival compared to complete resection alone. The importance of information concerning preselection of good responders has become increasingly evident. The purpose of our study is the establishment of a preselection of good responders for CDDP-based adjuvant chemotherapy. We investigated protein expressions comparing intensity between parent strains (H69 and PC14 lung cancer cultured cells) and resistant strains against CDDP using 2-dimensional polyacrylamide gel electrophoresis (2-DE). Immunohistochemically, we evaluated the relationship between protein expression associated with CDDP-resistance and the clinical effects of platinum-based postoperative adjuvant chemotherapy using 126 surgically-resected NCLC materials. We detected 2 kinds of polypeptides that changed expression levels on 2-DE gels. The analyses of the amino acid sequence showed that these polypeptides were reticulocalbin (RCN) and glutathione-S-transferase-pi (GST-pi). The 2-DE analysis showed decreased expression in RCN and overexpression in GST-pi with the acquisition of CDDP-drug resistance. RCN-transfectant of H69 CDDP-resistant strain showed intermediate sensitivity between the parent strain and the CDDP-resistant strain. RCN-positive cases showed a statistically significant better disease-free survival only in the cases receiving postoperative platinum-based adjuvant chemotherapy after curative resection (p = 0.007). In addition, cases that were both RCN-positive and GST-pi-negative showed a statistically significantly better outcome (p = 0.0150). In the cases without postoperative adjuvant chemotherapy no relationship between the outcome and these expressions was seen. The evaluation of RCN and GST-pi might provide valuable information concerning postoperatively therapeutic strategy from the standpoint of individualized postoperative therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
10
pubmed:volume
117
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
460-8
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:15900595-Amino Acid Sequence, pubmed-meshheading:15900595-Calcium-Binding Proteins, pubmed-meshheading:15900595-Cancer Vaccines, pubmed-meshheading:15900595-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:15900595-Cell Line, Tumor, pubmed-meshheading:15900595-Cell Survival, pubmed-meshheading:15900595-Chemotherapy, Adjuvant, pubmed-meshheading:15900595-Cisplatin, pubmed-meshheading:15900595-Cloning, Molecular, pubmed-meshheading:15900595-DNA, Complementary, pubmed-meshheading:15900595-Glutathione S-Transferase pi, pubmed-meshheading:15900595-Glutathione Transferase, pubmed-meshheading:15900595-Humans, pubmed-meshheading:15900595-Isoenzymes, pubmed-meshheading:15900595-Lung Neoplasms, pubmed-meshheading:15900595-Molecular Sequence Data, pubmed-meshheading:15900595-Peptide Fragments, pubmed-meshheading:15900595-Transfection, pubmed-meshheading:15900595-Tumor Markers, Biological
pubmed:year
2005
pubmed:articleTitle
Identification of postoperative adjuvant chemotherapy responders in non-small cell lung cancer by novel biomarker.
pubmed:affiliation
Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. thirano@tokyo-med.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't